A
new FDA guidance document has been issued: “Revised Preventive Measures to
Reduce the Possible Risk of Transmission of CJD and Variant CJD by Blood and
Blood Products.”
Tests
are being developed to detect CJD and vCJD infections in blood and plasma donors.
However, until suitable donor screening tests become available, FDA continues
to recommend interim preventive measures based on the available scientific data
and the evolving state of knowledge regarding these diseases. FDA may update
this guidance in the future, in light of developments in testing technology, epidemiological
information, and the impact of these recommendations on the supply of blood and
blood-derived products.
Posted by Dr. Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources